We believe that Diasome is poised to make a significant impact on the care of people with these conditions, and we look forward to being part of their success.
Cleveland, OH (PRWEB) March 04, 2014
Diasome Pharmaceuticals, Inc. (http://www.diasome.com) has announced that it has entered into an exclusive investment advisory engagement with McDonald Partners LLC, (http://www.mcdonald-partners.com) a Cleveland, Ohio company that provides full service brokerage, financial advisory and investment banking services to individual, institutional and corporate clients. Led by its founder, Thomas McDonald, and Senior Vice President, Kerry Watterson, the collaboration between Diasome and McDonald Partners is focused on Diasome’s current round of funding, the proceeds of which will be used to continue the development of HDV-Insulin, its late-stage human clinical drug candidates in Type 1 and Type 2 diabetes.
“We are pleased to partner with Diasome’s team on the development of their novel, breakthrough therapies for diabetes and obesity,” said Mr. McDonald. “We believe that Diasome is poised to make a significant impact on the care of people with these conditions, and we look forward to being part of their success.”
Commenting on this engagement, Robert Geho, Diasome’s Chief Executive Officer, stated, “Tom and Kerry, along with their firm’s advisors, bring considerable experience and enthusiasm to our development efforts, and we are delighted to have the opportunity to collaborate with them. The collaboration between our companies broadens our ability to partner with the investment community and to access strategic sources of expertise and funding.”
About Diasome Pharmaceuticals, Inc.
Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism, the Company’s pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a significant impact in treating obesity.
Diasome’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle, or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. It is generally recognized by diabetologists that the currently available forms of injected insulin used by all Type 1 diabetic patients and a significant percentage of people with Type 2 diabetes do not function in the body in the same way as naturally produced insulin. Because insulin tells the body when and how to store glucose, the ideal insulin therapy would function as closely to normal insulin as possible. Diasome’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by, for the first time, enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells.
About McDonald Partners, LLC
Founded by Thomas McDonald, McDonald Partners LLC is headquartered in Cleveland, Ohio, with additional offices in Maumee, Ohio, Ann Arbor, Michigan, Palm Beach, Florida and Chicago, Illinois. They are a full-service brokerage and investment advisory firm, offering comprehensive solutions with a customer-centric focus. From trust services to business and personal financial planning and investment strategies, McDonald Partners’ specialized approach allows them to create a customized plan based on their client’s financial goals.